Crinetics Pharmaceuticals, Inc. (CRNX) Form 10-Q — Aug 3, 2026
Crinetics Pharmaceuticals reported total revenue of $25.1 million for the second quarter of 2026, driven by the commercial launch of its acromegaly treatment PALSONIFY, while net loss widened to $120.9 million. A subsequent event disclosure reveals that Vertex Pharmaceuticals has agreed to acquire Crinetics for $85.00 per share in cash, with the transaction currently expected to close in the third quarter of 2026 subject to shareholder and regulatory approval.
Key figures
- Eps
- -$1.14
- Revenue
- $25.1 million
- Net Income
- -$120.9 million
- Total Assets
- $1,321.9 million
- Cash Position
- $55.5 million
- Termination Fee
- $350.5 million
- Q2 Product Revenue
- $24.0 million
- Investment Securities
- $1.15 billion
- Total Cash And Investments
- $1.2 billion
- Merger Consideration Per Share
- $85.00
Price after filing
1 day: 0.0%7 days: +0.6%30 days: +1.6%
Close on the filing date to close N calendar days later (from $83.63). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.